NL8800823A - Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten. - Google Patents

Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten. Download PDF

Info

Publication number
NL8800823A
NL8800823A NL8800823A NL8800823A NL8800823A NL 8800823 A NL8800823 A NL 8800823A NL 8800823 A NL8800823 A NL 8800823A NL 8800823 A NL8800823 A NL 8800823A NL 8800823 A NL8800823 A NL 8800823A
Authority
NL
Netherlands
Prior art keywords
treatment
selective dopamine
receptor agonist
pharmaceutical composition
active agent
Prior art date
Application number
NL8800823A
Other languages
English (en)
Dutch (nl)
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878708626A external-priority patent/GB8708626D0/en
Priority claimed from GB878708898A external-priority patent/GB8708898D0/en
Priority claimed from GB878710062A external-priority patent/GB8710062D0/en
Priority claimed from GB878720366A external-priority patent/GB8720366D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of NL8800823A publication Critical patent/NL8800823A/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NL8800823A 1987-04-10 1988-03-31 Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten. NL8800823A (nl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB8708626 1987-04-10
GB878708626A GB8708626D0 (en) 1987-04-10 1987-04-10 Indolophenanthridines
GB8708898 1987-04-14
GB878708898A GB8708898D0 (en) 1987-04-14 1987-04-14 Indolophenanthridines
GB878710062A GB8710062D0 (en) 1987-04-28 1987-04-28 Indolophenanthridines
GB8710062 1987-04-28
GB878720366A GB8720366D0 (en) 1987-08-28 1987-08-28 Dopamine d1 receptor agonists
GB8720366 1987-08-28

Publications (1)

Publication Number Publication Date
NL8800823A true NL8800823A (nl) 1988-11-01

Family

ID=27449909

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8800823A NL8800823A (nl) 1987-04-10 1988-03-31 Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten.

Country Status (11)

Country Link
US (1) US4855306A (it)
JP (1) JPS63258819A (it)
KR (1) KR880012227A (it)
AU (1) AU1440088A (it)
DE (1) DE3811274A1 (it)
DK (1) DK193588A (it)
FR (1) FR2613623A1 (it)
GB (1) GB2205495A (it)
IT (1) IT1219906B (it)
NL (1) NL8800823A (it)
SE (1) SE8801275L (it)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
KR101072885B1 (ko) * 2002-05-17 2011-10-17 듀크 유니버시티 비만치료방법
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
DE10312809A1 (de) * 2003-03-21 2004-09-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pramipexol zur Reduzierung übermäßiger Nahrungsaufnahme bei Kindern
US20040266794A1 (en) * 2003-03-21 2004-12-30 Boehringer Ingelheim International Gmbh Pramipexole for the reduction of excessive food intake for children
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
US20100168085A1 (en) * 2003-05-22 2010-07-01 Yesa Research And Development Co. Ltd. At The Weizmann Institute Of Science Dopamine and agonists and antagonists thereof for modulation of suppressive activity of CD4+CD25+ regulatory T cells
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
CA2553207A1 (en) * 2004-01-13 2005-08-04 Kishore M. Gadde Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
CA2565154A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
WO2006119353A2 (en) * 2005-05-03 2006-11-09 University Of South Carolina Dopamine receptor agonists in the treatment and prevention of hiv-induced dementia
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
CN101588795A (zh) 2006-11-09 2009-11-25 奥雷西根治疗公司 包含中间快速溶解层的分层药物制剂
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
RU2483082C1 (ru) * 2009-08-27 2013-05-27 Дайкин Индастриз, Лтд. Технологическая добавка, композиция для формования, маточная смесь технологической добавки и формовое изделие
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
HUE049859T2 (hu) 2012-06-06 2020-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatnak kitett páciensekben túlsúly és elhízás kezelésére szolgáló eljárásban történõ alkalmazásra

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3402392A1 (de) * 1984-01-25 1985-08-01 Sandoz-Patent-GmbH, 7850 Lörrach Neue ergolinderivate, deren herstellung und deren verwendung

Also Published As

Publication number Publication date
GB2205495A (en) 1988-12-14
JPS63258819A (ja) 1988-10-26
DK193588A (da) 1988-10-11
US4855306A (en) 1989-08-08
IT1219906B (it) 1990-05-24
IT8847814A0 (it) 1988-04-05
SE8801275D0 (sv) 1988-04-08
KR880012227A (ko) 1988-11-26
SE8801275A0 (sv) 1988-10-19
GB8808125D0 (en) 1988-05-11
SE8801275L (sv) 1988-10-19
AU1440088A (en) 1988-10-13
FR2613623A1 (fr) 1988-10-14
DK193588D0 (da) 1988-04-08
DE3811274A1 (de) 1988-10-27

Similar Documents

Publication Publication Date Title
NL8800823A (nl) Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten.
JP4925074B2 (ja) ミルタザピンと１種以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物
JP2003506483A (ja) シクロベンザプリンおよびその組成物による全般性不安障害の処置
WO2014052935A2 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
KR101869185B1 (ko) 혈액학적 장애의 치료에 사용하기 위한 glyt1 억제제
JPH0667839B2 (ja) ジオキソピペリジン誘導体の不安治療剤
JPH11503149A (ja) 基底核神経回路の不機能化に随伴する神経精神病症候群の治療のためのイミダゾ［１，２−ａ］ピリジン−３−アセトアミド誘導体の使用
JPH085787B2 (ja) 痴呆及び脳血管障害予防・治療剤並びに血小板凝集抑制剤
WO2001052855A2 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
WO2001008705A1 (fr) Remedes contre les douleurs neurogenes
WO1999032108A1 (en) Org-5222 in the treatment of depression
AU2002352625A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
HUT71464A (en) Pharmaceutical compositions containing tetrahydro-benz[c,d] indole-6-carboxamides al preventing emesis and treating sexual dysfunction
KR20000015805A (ko) 일산화질소 합성을 증가시키는 방법
JP2012522033A (ja) 気分障害の治療における低用量ピパンペロン
JPH0699310B2 (ja) アセトアルデヒド解毒剤
JP2006516629A (ja) 置換キノリンおよび置換ジフェニルスルホンを含有する組成物および方法
EP1758566A2 (en) Use of cb2 receptors agonists for the treatment of huntington"s disease
EP0663209A2 (en) Medicament for inhibiting the effects of amyloidogenic proteins
EA003671B1 (ru) Комбинация рилузола с альфа-токоферолом
KR102527378B1 (ko) 2'-fl을 함유하는 도파민 감소로 말미암아 발생하는 질환의 개선, 예방 또는 치료용 조성물
US20240252467A1 (en) Treatment of mental illness via administration of buntanetap and analogues thereof
WO1999008675A1 (fr) Agents therapeutiques pour traiter le colon irritable
EP0334674A2 (en) Use of isoxazolinones as cerebro-active drugs
JPH04270223A (ja) 療法的に活性なオルガノシラン誘導体を含む医薬組成物およびその調製方法

Legal Events

Date Code Title Description
A1A A request for search or an international-type search has been filed
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
BV The patent application has lapsed